S. Bilgin Et Al. , "Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study," Irish Journal of Medical Science , vol.191, no.4, pp.1647-1652, 2022
Bilgin, S. Et Al. 2022. Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study. Irish Journal of Medical Science , vol.191, no.4 , 1647-1652.
Bilgin, S., Kurtkulagi, Ö., Duman, T. T., Tel, B. M. A., Kahveci, G., Kiran, M., ... Erge, E.(2022). Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study. Irish Journal of Medical Science , vol.191, no.4, 1647-1652.
Bilgin, Satilmis Et Al. "Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study," Irish Journal of Medical Science , vol.191, no.4, 1647-1652, 2022
Bilgin, Satilmis Et Al. "Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study." Irish Journal of Medical Science , vol.191, no.4, pp.1647-1652, 2022
Bilgin, S. Et Al. (2022) . "Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study." Irish Journal of Medical Science , vol.191, no.4, pp.1647-1652.
@article{article, author={Satilmis Bilgin Et Al. }, title={Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study}, journal={Irish Journal of Medical Science}, year=2022, pages={1647-1652} }